A Single-Dose Study of the Safety and Tolerability of REGN475(SAR164877) in Healthy Subjects
Completed · Phase 1
Conditions studied: Healthy
In brief
This is a randomized, double-blind, placebo-controlled single-dose study of the safety and tolerability of intravenously administered REGN475 in healthy volunteers. The primary objective of the study is to assess the safety and tolerability of REGN475. The secondary objectives are to characterize the pharmacokinetic and immunogenicity profiles of REGN475.
Key facts
- Study ID
- NCT00856310
- Run by
- Regeneron Pharmaceuticals
- People needed
- 56
- Starts
- 2009-02-01
- Expected to finish
- 2009-11-01
- Last updated by the study team
- 2012-05-10
Who can join
Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Altoona, Pennsylvania, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.